Practice bulletin no. 113: Inherited thrombophilias in pregnancy

Obstetrics and Gynecology

Volumn 116, Issue 1, 2010, Pages 212-222

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTITHROMBIN; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 5 LEIDEN; DALTEPARIN; ENOXAPARIN; ESTROGEN; GESTAGEN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN C; PROTEIN S; PROTHROMBIN; TINZAPARIN; WARFARIN;

ANTICOAGULATION; ANTITHROMBIN DEFICIENCY; DISEASE ASSOCIATION; FEMALE; FETUS WASTAGE; HEMOSTASIS; HIGH RISK POPULATION; HUMAN; INTRAUTERINE GROWTH RETARDATION; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK ASSESSMENT; SCREENING; SOLUTIO PLACENTAE; THROMBOPHILIA; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

ANTITHROMBIN III; ANTITHROMBIN III DEFICIENCY; FACTOR V; FEMALE; HEMOSTASIS; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PROTEIN C DEFICIENCY; PROTHROMBIN; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 77954118594     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181e8b050     Document Type: Review

References (66)

1. Lockwood CJ, Krikun G, Rahman M, Caze R, Buchwalder L, Schatz F. The role of decidualization in regulating endo-metrial hemostasis during the menstrual cycle, gestation, and in pathological states. Semin Thromb Hemost 2007;33: 111-117 (Level III)
2. Lockwood CJ, Krikun G, Schatz F. The decidua regulates hemostasis in human endometrium. Semin Reprod Endocrinol 1999;17:45-51. (Level III)
3. Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003;16:153-168 (Level III)
4. Paidas MJ, Ku DH, Lee MJ, Manish S, Thurston A, Lockwood CJ, et al. Protein Z, protein S levels are lower in patients with thrombophilia and subsequent pregnancy complications. J Thromb Haemost 2005;3: 497-501. (Level II-3)
5. Hellgren M. Hemostasis during normal pregnancy and puer-perium. Semin Thromb Hemost 2003;29:125-130 (Level III)
6. Gherman RB, Goodwin TM, Leung B, Byrne JD, Hethumumi R, Montoro M. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol 1999;94:730-734 (Level II-3)
7. Chang J, Elam-Evans LD, Berg CJ, Herndon J, Flowers L, Seed KA, et al. Pregnancy-related mortality surveillance-United States, 1991-1999. Morb Mortal Wkly Rep Surveill Summ 2003;52:1-8. (Level II-3)
8. Scifres CM, Macones GA. The utility of thrombophilia testing in pregnant women with thrombosis: fact or fiction? Am J Obstet Gynecol 2008;199:344.e1-344. e7. (Level III)
9. Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet 2001;109:369-384 (Level III)
10. Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342:374-380 (Level II-3) (Pubitemid 30084535)
11. Zotz RB, Gerhardt A, Scharf RE. Inherited thrombophilia and gestational venous thromboembolism. Best Pract Res Clin Haematol 2003;16:243-259 (Level III)
12. Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women [letter]. Thromb Haemost 1990;63:319-320 (Level III)
13. De Stefano V, Leone G, Mastrangelo S, Tripodi A, Rodeghiero F, Castaman G, et al. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S [letter]. Thromb Haemost 1994;71:799-800. (Level III)
14. Marlar RA, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost 1990;16:299-309. (Level III)
15. Goodwin AJ, Rosendaal FR, Kottke-Marchant K, Bovill EG. A review of the technical, diagnostic, and epidemio-logic considerations for protein S assays. Arch Pathol Lab Med 2002;126:1349-1366 (Level III)
16. Fardella P, Parra M, Conte G, Flores C, Munoz H, Soto L, et al. Free protein S (PS) in normal pregnancy: a comparison between two analytical methods [Spanish]. Rev Med Chil 2005;133:633-638 (Level III)
17. Friederich PW, Sanson BJ, Simioni P, Zanardi S, Huisman MV, Kindt I, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis [published errata appear in Ann Intern Med 1997;127:1138; Ann Intern Med 1997; 126:835]. Ann Intern Med 1996;125:955-960 (Level II-2)
18. Carraro P. Guidelines for the laboratory investigation of inherited thrombophilias. Recommendations for the first level clinical laboratories. European Communities Confederation of Clinical Chemistry and Laboratory Medicine, Working Group on Guidelines for Investigation of Disease. Clin Chem Lab Med 2003;41:382-391 (Level III)
19. Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest 1982;14:127-141 (Level III)
20. Peng F, Labelle LA, Rainey BJ, Tsongalis GJ. Single nucleotide polymorphisms in the methylenetetrahydro-folate reductase gene are common in US Caucasian and Hispanic American populations. Int J Mol Med 2001; 8:509-511 (Level III)
21. Domagala TB, Adamek L, Nizankowska E, Sanak M, Szczeklik A. Mutations C677T and A1298C of the 5,10-methylenetetrahydrofolate reductase gene and fasting plasma homocysteine levels are not associated with the increased risk of venous thromboembolic disease. Blood Coagul Fibrinolysis 2002;13:423-431 (Level II-3)
22. McColl MD, Ellison J, Reid F, Tait RC, Walker ID, Greer IA. Prothrombin 20210 G->A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. BJOG 2000;107:565-569 (Level III)
23. den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998;80:874-877 (Meta-Analysis)
24. Eichinger S. Homocysteine, vitamin B6 and the risk of recurrent venous thromboembolism. Pathophysiol Haemost Thromb 2003;33:342-344 (Level III) (Pubitemid 40278705)
25. den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005;3:292-299 (Meta-Analysis)
26. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators [published erratum appears in N Engl J Med 2006;355:746]. N Engl J Med 2006;354:1567-1577 (Level I)
27. den Heijer M, Willems HP, Blom HJ, Gerrits WB, Cattaneo M, Eichinger S, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood 2007;109: 139-144 (Level I)
28. Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, et al. Thrombophilia in pregnancy: a systematic review. Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Br J Haematol 2006;132:171-196 (Meta-Analysis)
29. Kosmas IP, Tatsioni A, Ioannidis JP. Association of Leiden mutation in factor V gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. J Hypertens 2003;21:1221-1228 (Meta-Analysis)
30. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003;361:901-908 (Meta-Analysis)
31. Dudding TE, Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis. Thromb Haemost 2004;91:700-711 (Meta-Analysis) (Pubitemid 38477450)
32. Nelen WL, Blom HJ, Steegers EA, den Heijer M, Eskes TK. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. Fertil Steril 2000;74:1196-1199 (Meta-Analysis)
33. Lissalde-Lavigne G, Fabbro-Peray P, Cochery-Nouvellon E, Mercier E, Ripart-Neveu S, Balducchi JP, et al. Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case-control 'NOHA first' study. J Thromb Haemost 2005;3:2178-2184 (Level II-2)
34. Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996;348:913-916 (Level II-2)
35. Dizon-Townson D, Miller C, Sibai B, Spong CY, Thom E, Wendel G Jr, et al. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Obstet Gynecol 2005;106:517-524 (Level II-2)
36. Silver RM, Zhao Y, Spong CY, Sibai B, Wendel G Jr, Wenstrom K, et al. Prothrombin gene G20210A mutation and obstetric complications. Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (NICHD MFMU) Network. Obstet Gynecol 2010;115:14-20. (Level II)
37. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, et al. Increased frequency of genetic thrombo-philia in women with complications of pregnancy [published erratum appears in N Engl J Med 1999;341:384]. N Engl J Med 1999;340:9-13. (Level II-2)
38. Nurk E, Tell GS, Refsum H, Ueland PM, Vollset SE. Factor V Leiden, pregnancy complications and adverse outcomes: the Hordaland Homocysteine Study. QJM 2006;99:289-298 (Level II-2)
39. Currie L, Peek M, McNiven M, Prosser I, Mansour J, Ridgway J. Is there an increased maternal-infant prevalence of Factor V Leiden in association with severe pre-eclampsia? BJOG 2002;109:191-196 (Level II-2)
40. van Pampus MG, Wolf H, Koopman MM, van den Ende A, Buller HR, Reitsma PH. Prothrombin 20210 G: a mutation and Factor V Leiden mutation in women with a history of severe preeclampsia and (H)ELLP syndrome. Hypertens Pregnancy 2001;20:291-298 (Level III)
41. D'Elia AV, Driul L, Giacomello R, Colaone R, Fabbro D, Di Leonardo C, et al. Frequency of factor V, prothrombin and methylenetetrahydrofolate reductase gene variants in preeclampsia. Gynecol Obstet Invest 2002;53:84-87 (Level II-3)
42. Kahn SR, Platt R, McNamara H, Rozen R, Chen MF, Genest J Jr, et al. Inherited thrombophilia and pre-eclampsia within a multicenter cohort: the Montreal Preeclampsia Study. Am J Obstet Gynecol 2009;200:151. e1-9; discussion e1-5. (Level II-2)
43. Morrison ER, Miedzybrodzka ZH, Campbell DM, Haites NE, Wilson BJ, Watson MS, et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 2002;87:779-785 (Level II-2)
44. Livingston JC, Barton JR, Park V, Haddad B, Phillips O, Sibai BM. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am J Obstet Gynecol 2001;185:153-157 (Level II-3)
45. Lin J, August P. Genetic thrombophilias and preeclamp-sia: a meta-analysis. Obstet Gynecol 2005;105:182-192 (Meta-Analysis)
46. Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol 2002;101:6-14. (Meta-analysis)
47. Howley HE, Walker M, Rodger MA. A systematic review of the association between factor V Leiden or prothrom-bin gene variant and intrauterine growth restriction. Am J Obstet Gynecol 2005;192:694-708. (Meta-Analysis)
48. Franchi F, Cetin I, Todros T, Antonazzo P, Nobile de Santis MS, Cardaropoli S, et al. Intrauterine growth restriction and genetic predisposition to thrombophilia. Haematologica 2004;89:444-449 (Level II-2)
49. Verspyck E, Borg JY, Le Cam-Duchez V, Goffinet F, Degre S, Fournet P, et al. Thrombophilia and fetal growth restriction. Eur J Obstet Gynecol Reprod Biol 2004;113: 36-40. (Level II-2)
50. Infante-Rivard C, Rivard GE, Yotov WV, Genin E, Guiguet M, Weinberg C, et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Engl J Med 2002;347:19-25. (Level II-2) (Pubitemid 34728953)
51. Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK, et al. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study. Am J Clin Nutr 2000;71:962-968 (Level II-3)
52. Nurk E, Tell GS, Refsum H, Ueland PM, Vollset SE. Associations between maternal methylenetetrahydrofo-late reductase polymorphisms and adverse outcomes of pregnancy: the Hordaland Homocysteine Study. Am J Med 2004;117:26-31. (Level II-3)
53. Brill-Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, Geerts W, Kovacs M, Weitz JI, Robinson KS, Whittom R, Couture G; Recurrence of Clot in This Pregnancy Study Group. Safety of withholding heparin in pregnant women with a history of venous thromboembo-lism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med. 2000; 343:1439-1444 (Level I)
54. Kaandorp S, Di Nisio M, Goddijn M, Middeldorp S. Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD004734. DOI: 10.1002/14651858.CD004734. pub3. (Level III)
55. Clark SL, Porter TF, West FG. Coumarin derivatives and breast-feeding. Obstet Gynecol 2000;95:938-940 (Level III)
56. Orme ML, Lewis PJ, de Swiet M, Serlin MJ, Sibeon R, Baty JD, et al. May mothers given warfarin breast-feed their infants? Br Med J 1977;1:1564-1565 (Level III)
57. Richter C, Sitzmann J, Lang P, Weitzel H, Huch A, Huch R. Excretion of low molecular weight heparin in human milk. Br J Clin Pharmacol 2001;52:708-710 (Level III)
58. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrom-botic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). American College of Chest Physicians. Chest 2008;133:844S-86S. (Level III)
59. Duhl AJ, Paidas MJ, Ural SH, Branch W, Casele H, Cox-Gill J, et al. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Pregnancy and Thrombosis Working Group. Am J Obstet Gynecol 2007;197:457.e1-457.21. (Level III)
60. Horlocker TT, Wedel DJ, Benzon H, Brown DL, Enneking FK, Heit JA, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003;28: 172-197 (Level III)
61. Holst J, Lindblad B, Bergqvist D, Garre K, Nielsen H, Hedner U, et al. Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzapa-rin, Logiparin). An experimental investigation in healthy volunteers. Blood Coagul Fibrinolysis 1994;5:795-803. (Level II-3)
62. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004;164:1965-1976 (Level III)
63. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-1457 (Level II-2)
64. Use of hormonal contraception in women with coexisting medical conditions. ACOG Practice Bulletin No. 73. American College of Obstetricians and Gynecologists. Obstet Gynecol 2006;107:1453-1472 (Level III)
65. Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med 1997;127:895-903. (Level III)
66. Comp PC, Zacur HA. Contraceptive choices in women with coagulation disorders. Am J Obstet Gynecol 1993; 168:1990-1993 (Level III)